---
title: "Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients"
description: "Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256269429.md"
published_at: "2025-09-07T10:09:35.000Z"
---

# Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients

> Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and a median overall survival of 17.0 months for patients receiving ivonescimab, compared to 14.0 months for those on placebo. The findings indicate consistent benefits across subgroups. Additionally, the HARMONi-A study in China has reached its overall survival clinical endpoint, with results to be shared at future conferences.

Akeso, Inc. has announced updated results from the global Phase III HARMONi clinical trial of ivonescimab, a PD-1/VEGF bispecific antibody. This update, shared by Summit Therapeutics, Akeso’s global partner, during the 2025 World Conference on Lung Cancer, highlights longer-term follow-up data of western patients showing an improving trend in overall survival (OS). The analysis revealed a hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS for western patients receiving ivonescimab was 17.0 months compared to 14.0 months for those receiving placebo. These findings demonstrate consistent benefits across various subgroups. Akeso has also announced that the HARMONi-A study conducted in China has reached its OS clinical endpoint, with results to be presented at future academic conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN67362) on September 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 康方生物報告 Cadonilimab 在一線 PD-L1 低表達胃癌研究中表現優於 PD-1 抑制劑 | 康方生物報告稱，卡多利單抗聯合化療在一項針對 PD-L1 CPS  | [Link](https://longbridge.com/en/news/272494568.md) |
| 康方生物更新了合同製造安排，補充協議的到期時間設定為 2039 年 | 康方生物已更新與 CTTQ-Akeso 及其他方的合同製造安排，確認補充協議將持續至 2039 年 8 月 29 日。該協議允許根據必要性和市場條件簽訂新合同。單克隆抗體產品的年度採購上限是根據歷史數據和市場需求設定的，定價基於製造成本加上 | [Link](https://longbridge.com/en/news/273684258.md) |
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |
| 特朗普宣佈 5500 億日本投資正式啓動，首批聚焦油氣、發電、關鍵礦產 | 特朗普稱關税促成大規模投資，三個 “大項目” 涉及得州油氣戰略、俄亥俄州發電和佐治亞州關鍵礦產領域；燃氣發電廠將是 “史上最大”，墨西哥灣的 LNG 設施將推動出口並鞏固美國的能源主導低地位，關鍵礦產設施將結束美國對外依賴。 | [Link](https://longbridge.com/en/news/276173721.md) |
| “10-15 天” 最後通牒？特朗普：美伊必須達成有意義協議，否則發生 “糟糕的事” | 週四特朗普稱，預計未來十天左右知道能否與伊朗達成協議；內塔尼亞胡警告伊朗，以色列 “為任何情況做好準備”，強調以方正與美國 “並肩作戰” 應對伊方威脅。國際原子能機構總幹事稱，美國在中東軍事集結意味着，伊朗的外交窗口正在關閉。週三消息稱，美 | [Link](https://longbridge.com/en/news/276394487.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
